Student-Led Research Grants Also Available!

The Next Research Funding Deadline is July 31, 2021

Proposals should be submitted via email to info@nnecos.org.

2021 Research Proposal Elements / Application Template

CALL FOR PROPOSALS

The Northern New England Clinical Oncology Society (NNECOS) is seeking proposals for investigative projects of value to the Northern New England community of cancer care providers. Our goal is fund one or more proposals, up to a total of $20,000 for the July 2021 application cycle. Eligible candidates will be a current NNECOS member in good standing. Fellows and members of the interdisciplinary-care team are strongly encouraged to apply. Projects should align with our mission to promote the highest quality care for patients with cancer and blood disorders in our region. Preference will be given to projects promoting collaboration among NNECOS institutions (academic and community).

GENERAL INSTRUCTIONS

Proposals should be prepared in 11-point font, Arial, or Times New Roman, utilizing one-inch margins.

PROPOSAL ELEMENTS

  1. Page 1Abstract: 250 words or less stating the Background, Hypothesis, Proposed Methods, and Interpretation of Results. 
  2. Pages 2-3 - Body (Submissions exceeding two pages will be returned to the PI): 
    • Section 1 - Introduction with Hypothesis and Objective(s) – 2 SHORT paragraphs. (NOTE: The Review committee is MORE interested in Methods, Statistics and Analysis of Results
    • Section 2 - Methods with Statistics (Except for small pilot/feasibility studies, statistics should be provided to support sample sizes.) 
    • Section 3 - Analysis of Results – What do you expect the results to show and how will you interpret the results? 
  3. Page 4 - Budget, References 
    • Budget: Must be clearly outlined. Materials and funds for services of collaborating facility employees required in the operations of a project (i.e., research coordinator, statistician, etc., in alignment with national averages for their role) are examples of items to include in the budget. If the proposal is part of a larger project, the total amount of funding and its sources should be disclosed. Indirect costs and salary support for academic attending physicians and private practice providers should not be included. 
    • References: Pertinent journal and abstract references to support proposal

    NOTIFICATION

    Awardees will be notified in approximately six to eight weeks, be required to submit progress reports to NNECOS, submit the results of the research for poster presentation and if invited, present a final report of the research to the NNECOS annual meeting.


    APPLICATION DEADLINE
    !
    Completed applications must be received via email no later than 11:59pm on the stated deadline.

    Please note NNECOS is unable to fund indirect costs or investigator salaries as part of the grant budget.

    Since the program’s inception in 2008, the NNECOS Research Funding Program has awarded more than $158,500 to worthy projects of value to the Northern New England region.

    Congratulations to these 2020 NNECOS Research Grant Recipients

    Cycle 2

    Diego Andrianzen, M.D., Assistant Professor of Medicine

    and

    Neil Zakai, M.D., M.Sc., Associate Professor of Medicine

    Hematology/Oncology Division, Larner College of Medicine at the University of Vermont

    Diego Andrianzen, M.D. and Neil Zakai, M.D., M.Sc.,

    Identifying Factors Associated With Cardiovascular Disease In Myelodysplastic Syndromes: An Analysis Of The Seer-Medicare Database

    The primary objective of this study is to determine the sociodemographic and patient-specific clinical risk factors associated with increased risk of CVD and cardiovascular mortality in patients with MDS. The secondary objective is to determine the impact of MDS-specific therapeutic interventions (hypomethylating agents, iron chelation and growth factors) on hazard for new CVD or cardiovascular mortality in MDS patients.

    Principal Investigator: Hibba tul Rehman MD

    Mentors: Kim Dittus MD, Steven Ades MD, Michael Toth, PhD.

    Co investigators: Saranya Kodali MD, Eswar Tipirneni MD, Farrah Khan MD


    Aim 1 (Primary objective): To assess whether a structured exercise program offered via a virtual platform will be feasible in NSCLC patients undergoing active treatment for advanced stage (III and VI) disease.

    Aim 2 (Secondary objective 1): To assess the functional gains/stability in above cohort, measured by 6 minute walk test for estimation of gait speed, 30 seconds sit to stand count, and grip strength. We will assess ASMI (axial skeletal muscle index) for an assessment of muscle mass (using routine CT scans done for assessment of response to therapy, as part of standard of care (SOC)).

    Aim 3 (Secondary objective 2): To follow up on the clinical outcomes (progression free survival (PFS), overall survival (OS), response rate (RR) etc.) of this group and compare with historical controls.





    Prevention of sarcopenia in advanced stage NSCLC patients, undergoing first line treatment with chemotherapy / chemoimmunotherapy, through a structured, virtual exercise program: A pilot study.


    Congratulations to the 2019 NNECOS Research Grant Recipients

    Cycle 2


    VTE Risk Assessment and Prevention in Cancer Patients in the Community Oncology Setting 

    Learn more about the work of this group Successful Model for Guideline Implementation to Prevent Cancer-Associated Thrombosis: Venous Thromboembolism Prevention in the Ambulatory Cancer Clinic

    Cycle 1



    • Examination of Attitudes, Beliefs and Practices Regarding Point of Care Genetic Testing Among Northern New England Medical Oncologists - Marie E. Wood, MD, Bernard Cole, PhD, YongLi Ji, MD, PhD, Jens Reuter, MD, Susan Miesfeldt, MD - $9,000
    • Stage at Presentation and Travel Time for Patients with Cervical Cancer Treated at a Tertiary Care Hospital with Rural Catchment Areas in Northern New England – Johanna Kelley, MD, Evelyn Cantillo, MD, MPH, Carole McBride, PhD - $8,000

    Congratulations to the 2017 NNECOS Research Grant Recipients

    NNECOS awarded a total of $45,694 in research grants to 2017 applicants

    Cycle 2


      

    • DNA repair landscape of discordant sibling pairs from hereditary breast cancer families, Kara Landry, MD, Larner College of Medicine, University of Vermont
    • Assessing the Utility of Predictive Early Chimerism Analysis Following Haploidentical Stem Cell
      Transplant
      , Raphael Lizcano, MD, John Hill, Jr, MD - Dartmouth-Hitchcock/White River Junction, VA

    Cycle 1


    • Pilot Study involving Active Surveillance with CT Imaging and Liquid Biopsies for Inoperable Stage IA Lung Cancer in the Elderly, Christopher Anker, MD, University of Vermont Medical Center
    • Use of a toxicity assessment questionnaire to evaluate clinical significance of the statin paclitaxel drug interaction, Michael Pelchat, RPh, NH Oncology-Hematology
    Congratulations to 2011 NNECOS Research Grant recipient, Ivette Emery, PhD on publication of your study results in the Journal of Neuro-oncology!  https://link.springer.com/article/10.1007/s11060-017-2422-z


    Past Projects Funded Include:

    • Clinical Trial Barrier Study
      • Assessment of perceived cost to the patient and other barriers to clinical trial participation. Weckstein DJ, Thomas CA, Emery IF, Shea BF, Fleury A, White ME, Chase E, Robinson C, Frazier S, Pilar C. J Oncol Pract. 2011 Sep;7(5):33

    • Exercise for Individuals with Stage IV Cancer
      • Litterini A, Cavanaugh J, Fieler V, Lee JQ.  Differential Effects of Cardiovascular and Resistance Exercise on Functional Mobility in Individuals with Advanced Cancer: A Randomized Trial. Arch Phys Med Rehabil. 2013;94:2329-35.

      • Litterini, A and Lee, J. “Exercise for Individuals with Metastatic Cancer.” APTA 2013 Combined Sections Meeting, Oncology Section Platform Presentation, San Diego, CA, 2013.

      • Litterini, A., and Fieler, V. “Differential Effects of Cardiovascular and Resistance Exercise on Functional Mobility in Individuals with Advanced Cancer: A Randomized Trial.” Poster Presentation, 2015 New England Cancer Survivorship Research Symposium, Harvard Medical School/ Dana-Farber Cancer Institute in Boston, MA, on April 2, 2015. Available [on-line]: http://dune.une.edu/pt_facpost/4

    • Head and neck cancer trial involving response to neoadjuvant chemotherapy
    Role of prostaglandin pathways in radiotherapy-induced mucositis.
    Steven M. Grunberg, Madhuri V. Vithala, Margaret Vizzard, Nathan Bradley Adams, Havaleh Marie Gagne, William Brundage, and Takamaru Ashikaga; Journal of Clinical Oncology 2013 31:15_suppl, e20509-e20509
    • Inhibition of stem cell pathways in a patient-derived GBM tumor model system.
    • Emery, Ivette et al.  Expression and Function of ABCG2 and XIAP in Glioblastomas. Journal of NeuroOncology May 2017. Volume 133(1) 47-57
    • Coagulation activation in brain neoplasms
      • Coagulation Activation in Brain Neoplasms, Swaroopa Yerrabothala, Brett L. Gourley, James C Ford, Syed Rakin Ahmed, Stephen J Guerin, Heather A Wishart, Camilo E Fadul and Deborah L. Ornstein; Blood 2017 130:3704; http://www.bloodjournal.org/content/130/Suppl_1/3704
    • DNA repair landscape in individuals with increased risk of breast cancer
      • Curtis, Adam & Rueter, Jens & Rajan, Shelia & Zhang, Rong & Shopland, Lindsay. (2018). Additive and synergistic inhibition of mantle cell lymphoma cell growth by combining olaparib with ibrutinib. Journal of Cellular Biochemistry. 119. 10.1002/jcb.26773. Download this paper. 
      • Poster at 2017 NNECOS Annual Meeting.
    • Social Media Usage within the Cancer Community of Northern New England
    • Thrombin Generation as a Predictive Biomarker for Venous thromboembolism in Patients with Pancreatic and Lung Cancer Undergoing Chemotherapy
    • Synergistic targeting of CLL cells with DNA repair and B cell receptor inhibitors - view the poster
    • Pilot study of the role of MDSCs and VISTA in immunology of chronic graft-versus-host disease following reduced intensity allogeneic bone marrow transplantation
    • Pilot Study involving Active Surveillance with CT Imaging and Liquid Biopsies for Inoperable Stage IA Lung Cancer in the Elderly
    • Use of a toxicity assessment questionnaire to evaluate clinical significance of the statin paclitaxel drug interaction
    • DNA repair landscape of discordant sibling pairs from hereditary breast cancer families
    • Assessing the Utility of Predictive Early Chimerism Analysis Following Haploidentical Stem Cell
      Transplant



    Northern New England Clinical Oncology Society
    P.O. Box 643
    Sandown, NH 03873-0643
    Telephone (603) 887-1948
    info@nnecos.org

    This website brought to you by:


    Powered by Wild Apricot Membership Software